Conference Reports for NATAP

Back

International AIDS Conference Durban, South Africa July 18-22, 2016     HIV Prevention at AIDS 2016 21st International AIDS Conference Durban, South Africa 18-22 July 2016 Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington- (08/08/16)   21st International AIDS Conference July 18-22, 2016 Durban, South Africa - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA - (08/05/16)   HIV CURE RESEARCH: A SURVEY OF AUSTRALIAN PEOPLE LIVING WITH HIV ON PERSPECTIVES, PERCEIVED BENEFITS AND WILLINGNESS TO PARTICIPATE IN TRIALS - (09/20/16)   Cure Research Ethics / Risk to Patients Who Participate - (08/19/16)   Aging at IAC / Durban 2016 , July 18-22 - (08/15/16)   Prevalence and immuno-metabolic associations of frailty in older Australian men living with HIV: a cross-sectional analysis - (08/10/16)   Optimizing the frequency of kidney safety monitoring in HIV-uninfected persons using daily oral tenofovir disoproxil fumarate pre-exposure prophylaxis - (08/10/16)   Cure / Vaccine Research - IAC Durban 2016, July 18-22 - (08/10/16)   Women's Studies at IAC / Durban 2016, July 18-22 - (08/10/16)   IAC/Durban 2016 - Key HIV HAART Studies, TB - (08/10/16)   Reported changes in PrEP and condom use in MSM during the open-label extension of the ANRS IPERGAY study - (08/10/16)   PrEP - Truvada / PrEP+ART / Long-Acting Cabotegravir / Dapirivine Vaginal Ring / On-Demand PrEP IPERGAY / Maraviroc PrEP - (08/10/16)   An exploratory assessment of the feasibility and acceptability of home-based support to streamline HIV pre-exposure prophylaxis (PrEP) delivery - (08/10/16)   Correlates for levels of self-reported PrEP adherence among Black men who have sex with men in 3 U.S. cities - (08/05/16)   HPTN 073: successful engagement of Black MSM into a culturally relevant clinical trial for pre-exposure prophylaxis (PrEP) - (08/05/16)   Persistence of Rilpivirine Following Single Dose of Long-Acting Injection - (08/04/16)   Injecting Cocaine But Not Smoking Crack Lowers HIV Control Chance in Methadone Users - Mark Mascolini (08/04/16)   Rapidly falling costs for new hepatitis C direct-acting antivirals (DAAs): potential for universal access - (08/04/16)   Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study - (08/04/16)   TURQUOISE-I Part 2: safety and efficacy of ombitasvir + paritaprevir/r ± dasabuvir with or without RBV in patients with HIV-1 and HCV GT1 or GT4 co-infection - (08/04/16)   CANCER TREATMENT IN ELDERLY INDIVIDUALS - National Cancer Institute: HIV+ have lower rates of cancer treatment when <70 years old; HIV+ less likely to receive treatment quickly - (08/04/16)   Adherence to antiretroviral therapy and neurocognitive impairment in South Africa / 55% neurocognitively impaired / 64% nonadherent - (08/04/16)   Adherence to antiretroviral therapy and neurocognitive impairment in South Africa / 55% neurocognitively impaired / 64% nonadherent - (08/04/16)   Antiretroviral treatment adherence, viremia, and psychiatric diagnosis throughout adolescence among perinatally HIV-infected youth..... - (08/04/16)   Low birth weight predicts post-partum deterioration in maternal virologic control among HIV-1 infected women in Bronx, NY, USA. - (08/04/16)   Neurocognitive Performance and Normative Comparison Data in HIV+ and HIV-Individuals in Rakai, Uganda - (08/04/16)   Neurocognitive Assessment in Nigeria The ICON Cohort - (08/04/16)   Differences in health-related quality of life highlight the different emphases of three frailty instruments in older Australian men living with HIV ....13% had HCV coinfection - (08/04/16)   Attrition across the HIV cascade of care among a diverse cohort of women living with HIV in Canada - (08/04/16)   Raltegravir containing antiretroviral therapy for prevention of mother to child transmission in a high risk population of HIV-infected pregnant women in Buenos Aires, Argentina: maternal and neonatal outcomes.... - (08/03/16)   The association of injectable progestin-only contraceptives and endogenous progestins with HIV target cell frequency in the cervix and HIV acquisition risk - (08/03/16)   Beyond cervical cancer: gynecological malignancies and treatment in HIV+ women - (08/03/16)   Association of markers of gut microbial translocation and inflammation with insulin resistance in HIV-infected persons - (08/03/16)   Adherence With Combination Antiretroviral Therapy (cART): Do Challenges Still Persist? "31% non-adherent" - (08/03/16)   Truvada PrEP, Vaginal Ring, Maraviroc PrEP, vaginal ring att Durban IAC 2016 July 18-22 - (08/03/16)   New Evidence: Why Do Young Women in Africa Have High Rates of HIV Infection? - (08/03/16)   Benefits of pre-exposure prophylaxis relative to drug resistance risk - (08/03/16)   Contribution of T cells to RANKL/OPG imbalance and bone loss in HIV infection - (07/29/16)   Satisfaction, Tolerability, and Acceptability of Cabotegravir (CAB) + Rilpivirine (RPV) Long-Acting Therapy: LATTE-2 Results - (07/29/16)   Incidence [increased a lot with aging] of neurological disorders among HIV-infected individuals with universal health care in Taiwan, 2000 through 2010 - (07/29/16)   Persistence of Rilpivirine Following Single Dose of Long-Acting Injection - (07/29/16)   Superior Outcomes with Same-Day HIV Testing and ART Initiation - (07/29/16)   HIV associated neurocognitive disorder in a peri-urban HIV clinic in KwaZulu-Natal, South Africa - (07/29/16)   Daily is better than thrice-weekly ATT in HIV patients with culture confirmed pulmonary TB,- a RCT from South India (CTRI-476/09, NCT00933790 ) Study initiation date : 14.09.2009 - (07/29/16)   GETTING THERE? LIFE EXPECTANCY BY HIV STATUS AND EDUCATION IN SWITZERLAND ...former & even moreso current IDUs, and smokers have much reduced life expectancy - (07/29/16)   Dolutegravir-Lamivudine as initial therapy in HIV-Infected, ARV naïve patients 48 Week Results of the PADDLE trial. - (07/29/16)   Raltegravir (RAL) 1200 mg Once Daily (QD) is Non-Inferior to RAL 400 mg Twice Daily (BID), in Combination with Tenofovir/Emtricitabine, in Treatment-Naïve HIV-1 Infected Subjects: Week 48 Results - (07/29/16)   CD8-Cell Exhaustions Predicts Primary HIV Infection Progression - HIV Causes CD8 Exhaustion-Occurs Early/Predicts HIV Progression - (07/29/16)   High Satisfaction With Injected Long-Acting CAB + RPV in LATTE-2 Trial - Mark Mascolini (07/29/16)   High Satisfaction With Injected Long-Acting CAB + RPV in LATTE-2 Trial - Mark Mascolini (07/28/16)   Which START Participants Got the Most Benefit From Early ART? - Mark Mascolini (07/28/16)   Only 4 New HIV Infections in 1013 HIV-Discordant Couples Using ART and PrEP - Integrated delivery of PrEP and ART results in sustained near elimination of HIV transmission in African HIV serodiscordant couples: final results from The Partners Demonstration Project - Mark Mascolini (07/28/16)   Which START Participants Got the Most Benefit From Early ART? - Mark Mascolini (07/28/16)   Post-ART and No-ART Controllers Similar in Primary Infection Trial/Cure Trials - Mark Mascolini (07/28/16)   Using phylogenetics of HIV to inform prevention among young black men who have sex with men in Chicago - HIV Transmission Clusters Offer Clues to HIV Risk in Young Black MSM - Mark Mascolini (07/28/16)   Using phylogenetics of HIV to inform prevention among young black men who have sex with men in Chicago - HIV Transmission Clusters Offer Clues to HIV Risk in Young Black MSM - Mark Mascolini (07/28/16)   Preventing 1 Infection With As-Needed PrEP Costs 3 to 4 Times More Than HIV Therapy - Mark Mascolini (07/27/16)   Higher Adherence Tied to 65% Protection With Dapivirine Vaginal Ring - Mark Mascolini (07/27/16)   Which START Participants Got the Most Benefit From Early ART? - Mark Mascolini (07/27/16)   Rilpivirine in Genital Tract 18 Months After One Long-Acting Injection - Mark Mascolini (07/27/16)   Only 60% of HIV Providers Can Answer 4 Easy Questions About Obamacare - National Survey of United States HIV Healthcare Providers about Affordable Care Act Knowledge and Attitudes - Mark Mascolini (07/27/16)   Higher Adherence Tied to 65% Protection With Dapivirine Vaginal Ring - Mark Mascolini (07/27/16)   Monthly Naltrexone for Alcohol Abuse Helps Viral Suppression After Prison Release - Mark Mascolini (07/27/16)   Incidence and correlates of STIs among black men who have sex with men participating in a US PrEP study - Mark Mascolini (07/27/16)   Enhanced Infection Prophylaxis Cuts Mortality 25% in ART Starters With Low CD4s - Mark Mascolini (07/27/16)   No HIV Infections in Clients of San Francisco PrEP Program - Mark Mascolini (07/27/16)   The impact of Universal Test and Treat on HIV incidence in a rural South African population ....Poor Linkage to Care Undermines Test-and-Treat in South African Trial.... - Mark Mascolini (07/27/16)   First-line Dolutegravir/3TC Controls HIV in 90% in Small Pilot Trial - Mark Mascolini (07/27/16)   Once-Daily (1200-mg) Raltegravir Noninferior to 400 mg Twice Daily - Mark Mascolini (07/27/16)   Adding RAL to 3-Drug First Regimen Does Not Cut Mortality in Low-CD4 Group - Mark Mascolini (07/27/16)   Switch to Single-Pill DTG/ABC/3TC Noninferior to Keeping Current ART - Mark Mascolini (07/27/16)   Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study - (07/26/16)   Increased risk of suicidal behaviour with use of efavirenz: Results from the START Trial - (07/26/16)   Raltegravir (RAL) 1200 mg Once Daily (QD) is Non-Inferior to RAL 400 mg Twice Daily (BID), in Combination with Tenofovir/Emtricitabine, in Treatment-NaÏve HIV-1 Infected Subjects: Week 48 Results - (07/26/16)   Dolutegravir-Lamivudine as initial therapy in HIV-Infected, ARV naÏve patients 48 Week Results of the PADDLE trial. - (07/26/16)   Superior Efficacy of Dolutegravir/Abacavir/Lamivudine FDC Compared With Ritonavir-Boosted Atazanavir Plus Tenofovir Disoproxil Fumarate/Emtricitabine FDC in Treatment-Naive Women With HIV-1 Infection: ARIA Study - (07/26/16)   12-week raltegravir-intensified quadruple therapy versus triple first-line ART reduces viral load more rapidly but does not reduce mortality in severely immunosuppressed African HIV-infected adults and older children: the REALITY trial - (07/26/16)   Data for Merck's Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation... - (07/25/16)   Renewed hope for HIV vaccine, new developments - (07/25/16)   Experiences with long acting injectable ART: a qualitative study among PLHIV participating in a Phase II study of Cabotegravir + Rilpivirine (LATTE-2) in the United States and Spain - (07/25/16)   Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 48 Results - (07/25/16)   Switching to Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination (DTG/ABC/3TC FDC) from a PI, INI or NNRTI Based Regimen Maintains HIV Suppression at 48 Weeks - (07/25/16)   Effect of injectable hormonal contraceptives on vaginal epithelium thickness and genital HIV target cell density in women recently infected with HIV - (07/25/16)   Impact of a fat-rich diet on the pathogenesis of SIV infection in the African green monkey host - "induced microbial translocation and elevated immune activation and inflammation/ impacted survival/ altered metabolism profile and liver " - (07/25/16)   HIV-associated alteration in gut microbiota are associated with increased inflammation and infection of enteric CD4+ T cells - (07/25/16)   Love with HIV: a latent class analysis of intimate relationships among women living with HIV enrolled in Canada's largest multisite community-based research study...."Nearly half of Canadian WLWH were not in relationships" - (07/25/16)   An HIV pre-exposure prophylaxis (PrEP) demonstration project and safety study for adolescent MSM ages 15-17 in the United States (ATN 113) - (07/22/16)   HIV-associated alteration in gut microbiota are associated with increased inflammation and infection of enteric CD4+ T cells - (07/22/16)   Aging & Inflammation: 10 yrs decreased life expectancy/T-cell activation remind high despite viral suppression/inflammation markers predict disease & death- "Pathophysiology of Non-Communicable Diseases in Treated HIV Infection: Is there a common path?" talk by Peter Hunt - (07/22/16)   Residual dapivirine ring levels indicate higher adherence to vaginal ring is associated with HIV-1 protection ......."Results suggest ring use is associated with at least 56% and potentially >75% protection when used consistently" - (07/22/16)   Long-term trends in mortality and AIDS-defining events among perinatally HIV-infected children across Europe and Thailand - (07/22/16)   CDC Study: Why the Disparities: The First National Look at HIV-Related Risk Behaviors Among Sexual Minority Male High School Students, United States, 2015 - High rates of injection drug use increases gay teens' HIV risk - (07/22/16)   Randomized trial of stopping or continuing ART among post-partum women with pre-ART CD4 >400 cells/mm3 (PROMISE 1077HS) ...." Shows Mixed Results" - Mark Mascolini - (07/22/16)   HCV Coinfection Not Tied to Higher HIV Load in Meta-Analysis - Mark Mascolini - (07/22/16)   Test-and-Treat in Uganda/Kenya Attains 80% HIV Control in 2 Years.... "UN AIDS 90-90-90 Target Exceeded" - Mark Mascolini - (07/22/16)   Immediate ART in START Trial Linked to Better Kidney Function - Mark Mascolini - (07/22/16)   Impact of Aging on non-AIDS Comorbidity in Large Spanish HIV Cohort - Mark Mascolini - (07/22/16)   Before- and After-Sex PrEP Working Despite Low Condom Use - Mark Mascolini - (07/22/16)   Two Methods Offer Good Mortality Prediction in Critically Ill HIV Patients - Mark Mascolini - (07/22/16)   HIV Life Expectancy Jumps 34 Years in Switzerland But Lags General Population - Mark Mascolini - (07/22/16)   TURQUOISE-I Part 2: safety and efficacy of ombitasvir + paritaprevir/r ± dasabuvir with or without RBV in patients with HIV-1 and HCV GT1 or GT4 co-infection - (07/20/16)   Drug-Drug Interactions Studies between HCV Antivirals Sofosbuvir/Velpatasvir and HIV Antiretrovirals in Healthy Volunteers - (07/20/16)   Sofosbuvir/Velpatasvir Yields 95% SVR12 in Patients With HCV/HIV - Mark Mascolini - (07/20/16)   Drug-Drug Interactions Studies between HCV Antivirals Sofosbuvir/Velpatasvir and HIV Antiretrovirals in Healthy Volunteers-2 - Mark Mascolini - (07/20/16)   Understanding high rates of HIV in young women in South Africa: Implications of the new evidence - (07/22/16)   Uncovering the role of the vaginal microbomein undermining PrEP efficacy in women - (07/20/16)   Role of vaginal microbiota in genital inflammation and enhancing HIV transmission - (07/20/16)   HIV infection in young women in Africa: An overview - (07/20/16)   Study results provide critical new data to guide HIV prevention and treatment efforts for women and girls - (07/20/16)   FTC/TDF (Truvada) for HIV Pre-Exposure Prophylaxis (PrEP) Utilization in the United States: 2012-2015 - (07/20/16)   Central nervous system impact of vorinostat, hydroxychloroquine and maraviroc combination therapy followed by treatment interruption in individuals treated during acute HIV infection (SEARCH 026) - (07/20/16)   HPTN 069 / ACTG A5305 Phase II Study of Maraviroc (MVC)-Containing Regimens for HIV PrEP in U.S. Women...."NO new infections....annual incidence rate 0%" - (07/20/16)   Sexual activity without condoms and risk of HIV transmission when the HIV positive partner is using suppressive ART: The PARTNER study - (07/20/16)   Deferred antiretroviral therapy is associated with lower eGFR in HIV-positive individuals with high CD4 counts - (07/20/16)   Mortality Prediction in HIV-Infected Persons with Critical Illness - (07/20/16)   Changes in Bone Mass after Discontinuation of PrEP with Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Young Men Who Have Sex with Men (YMSM): Extension Phase Results of Adolescent Trials Network (ATN) Study 110 - (07/20/16)   Efficacy of "On Demand" PrEP in the ANRS IPERGAY Open-Label Extension Study - (07/20/16)   Integrated delivery of PrEP and ART results in sustained near elimination of HIV transmission in African HIV serodiscordant couples: - (07/20/16)   No Transmissions in Couples With HIV+ Partner Undetectable on ART - Mark Mascolini - (07/19/16)   Vorinostat, HCQ, Maraviroc Do Not Delay Time to Rebound After Interruption - Mark Mascolini - (07/19/14)   Dolutegravir/Rilpivirine as Simpler Maintenance After Heavy Pretreatment - Mark Mascolini - (07/19/16)   Allogeneic Stem Cell Transplantation in HIV-1 infected individuals; the EpiStem Consortium - (07/19/16)   HIV Cure research - Are you really not optimistic that a cure will be possible? - 2016 Intl AIDS Conference Durban - (07/19/16)   Used consistently, monthly vaginal ring may be highly effective against HIV in women, suggest new analyses from ASPIRE - (07/19/14)   IPM's dapivirine ring may offer significant HIV protection when used consistently, new data analyses suggest - (07/18/16)   Vaginal Ring May Cut HIV Infection Risk if Used Consistently - (07/18/16)